Clinical Trial Update: Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating the combination of bevacizumab and erlotinib in hormone-refractory prostate cancer was terminated with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Columbia University | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-03-25